RBCC: Promising New Parkinson’s Therapies May Also Treat Brain Injuries

NOKOMIS, Fla.--(BUSINESS WIRE)--

As emerging biotech firm Rainbow Coral Corp. (OTCBB: RBCC.OB - News) closes in on a deal with a new clinical-stage company developing diagnostics and therapeutics for Parkinsons disease, exciting news is emerging that drugs used to treat the disease could also be beneficial to patients suffering from traumatic brain injuries.

Scientists reported last month that daily doses of a drug used to treat Parkinsons disease significantly improved function in severely brain-injured people thought to be beyond the reach of treatment. Researchers from 11 clinics enrolled 184 patients who recently had a traumatic brain injury from a car accident or from blows to the head in the study. The programs results, published in the New England Journal of Medicine, were highly encouraging.

Patients receiving daily doses of the Parkinsons drug amantadine showed improvements in coordination and communication beyond those of the control group. The study could be a turning point in the understanding and treatment of people with severe traumatic brain injuries, opening up Parkinsons treatments to a new market of thousands of patients.

RBCC is working hard to capitalize on the growing demand for effective treatments for Parkinsons and other neurological health issues. Last week, the company initiated discussions for a term sheet with an emerging biotech firm developing a pre-clinical therapeutic protein for the treatment of Parkinsons, traumatic brain injury and stroke.

Rainbow BioSciences is dedicated to developing new medical and research technology innovations to compete alongside companies such as Amgen Inc. (NASDAQ:AMGN),Cell Therapeutics, Inc. (NASDAQ: CTIC - News), Abbott Laboratories (NYSE:ABT) andAffymax, Inc.(NASDAQ:AFFY).

For more information on Rainbow BioSciences, please visit http://www.rainbowbiosciences.com/investors.

Follow us on Twitter atwww.twitter.com/RBCCinfo.

About Rainbow BioSciences

Rainbow BioSciences is a division ofRainbow Coral Corp.(OTCBB:RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.rainbowbiosciences.com]. For investment information and performance data on the company, please visitwww.RainbowBioSciences.com/investors.

Link:
RBCC: Promising New Parkinson’s Therapies May Also Treat Brain Injuries